~~<i id='50A7907B62'><strike id='50A7907B62'><tt id='50A7907B62'><pre id='50A7907B62'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

hotspot

explore

author：Wikipedia 2025-10-01 15:31:33 - browse：5728

ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

Arch declined to comment on the new fundraising.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen
Next article： What we’ve learned from the Aduhelm mess

entertainment

knowledge

focus

knowledge

focus

AdobeUsingonlineplatformssuchasGoFundMetosolicitdonationsforhealth-relatedneedscanhelppeopleaccessle

WSS

What affirmative action's end means to a medical student

The wait for US passports is creating travel purgatory and snarling summer plans

The biotech scorecard for Q3: 15 stock

Biogen Alzheimer’s drug launch off to slow start

For Medicare Advantage, Democrats want stronger protections around AI

BioAge raises $170M for combination therapy with Zepbound

hotspot

explore

entertainment

Cancer drug shortages should be causing more outrage

BioAge raises $170M for combination therapy with Zepbound

Medicare proposal to cover medical devices draws a mixed reaction

UpToDate has a racism problem: Dr. Stanley Goldfarb

Supreme Court strikes down use of affirmative action

Dexcom's push to bring CGM to type 2 diabetes patients

In age of alternative facts, a scholarly course on calling out crap

Skip the lead apron during X

BioMarin wins approval for gene therapy to treat hemophilia A

Senators start work on Medicare physician payment reform

knowledge

How Robert F. Kennedy Jr. distorted vaccine science

Security flaws in third

Medicare threatens to cut off funding for HCA's Mission hospital

Security flaws in third

KalVista pill reduced swelling 'attacks' caused by genetic disease

The dental labor crisis is a moment of opportunity

focus

knowledge

focus

focus